The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors
Els Lierman(KU Leuven), Jan Cools(Universitair Ziekenhuis Leuven)
Cited by 93
Related Papers
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia
|Blood|2019|63
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220
|Haematologica|2012|29
Single‐cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment
|HemaSphere|2025|4
Resistance to PSEN1-selective γ-secretase inhibitors in T-cell acute lymphoblastic leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2024|0